Targacept has announced that AstraZeneca will pursue the development of the company’s candidate AZD1446 as a treatment for Alzheimer’s disease.
AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor developed through a research collaboration conducted by Targacept and AstraZeneca.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the terms of a 2005 collaborative research and license agreement, AstraZeneca took responsibility for further development and potential commercialisation of AZD1446.
The drug will now move into a Phase II trial as an additional treatment to donepezil for patients with mild to moderate Alzheimer’s.
Targacept President and CEO J Donald deBethizy said that the planned evaluation of AZD1446 as an augmentation treatment in Alzheimer’s complements Targacept’s ongoing Phase IIb study of AZD3480 as a monotherapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
